NDA 021011 · Specgx LLC
Roxicodone
Oxycodone Hydrochloride · Oral
Last checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Aug 31, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
646
137 Phase 3, 50 recruiting
FAERS reports
92,014
81,137 serious, 32,198 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ROXICODONE Addiction, Abuse, and Misuse Because the use of ROXICODONE exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions ( 5.1 )] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of ROXICODONE, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ROXICODONE are essential [see Warnings and Precautions ( 5.2 )] . Accidental Ingestion Accidental ingestion of even one dose of ROXICODONE, especially by children, can result in a fatal overdose of...
What it is approved for
From the label in effect Apr 24, 2026.
ROXICODONE is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy [see Warnings and Precautions ( 5.1 )] , reserve opioid analgesics, including ROXICODONE for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ROXICODONE is an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1 ) Limitations of Use: Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including ROXICODONE for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 , 5.1 )
Mechanism: Oxycodone is a full opioid agonist and is relatively selective for the mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- ROXICODONE · OXYCODONE HYDROCHLORIDE 30MG · TABLET, ORAL · Prescription · TE AB
- ROXICODONE · OXYCODONE HYDROCHLORIDE 5MG · TABLET, ORAL · Prescription · TE AB
- ROXICODONE · OXYCODONE HYDROCHLORIDE 15MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxycodone" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- Opioid Prescription After Cesarean TrialPivotal-lookingCompleted
The George Washington University Biostatistics CenterAcademic, hospital or other
NCT04296396 · 5,521 participants · Start Sep 21, 2020 · Primary completion Apr 7, 2022
Drug: 0 to 20 tablets of oxycodone 5mg; Fixed opioid prescription · For: Pregnancy Related; Opioid Use; Pain
Sites: Birmingham, Alabama; Chicago, Illinois; New York, New York · 12 sites in all
- Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer PainPivotal-lookingCompleted
Gachon University Gil Medical CenterAcademic, hospital or other
NCT00478101 · 2,006 participants · Start Feb 2006
Drug: oxycodone fentanyl · For: Advanced Solid Cancers
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- Effect of Preventive Analgesia with Oxycodone and Parecoxib Sodium on the Chronification of Acute Post-operative PainPivotal-lookingNot yet recruiting
Ailin LuoAcademic, hospital or other
NCT06721988 · 1,316 participants (planned) · Start Jan 1, 2025 · Primary completion Dec 31, 2026
Drug: oxycodone and parecoxib sodium combinations; Placebo and parecoxib sodium combinations · For: Oxycodone; Chronic Pain, Postoperative
- A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic PainPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00361504 · 1,123 participants · Start Nov 2006 · Primary completion Jul 2008
Drug: Oxycodone CR; Tapentadol (CG5503) ER · For: Osteoarthritis, Hip; Osteoarthritis, Knee; Lower Back Pain and 1 more
Sites: Mesa, Arizona; Tucson, Arizona; Anaheim, California · 52 sites in all
- Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back PainPivotal-lookingCompleted
Seoul National University HospitalAcademic, hospital or other
NCT02883569 · 1,102 participants · Start Sep 2016 · Primary completion Dec 2020
Drug: ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac; codeine, oxycontine, IRcodone, Tramadol · For: Low Back Pain
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug dependence27,118
- pain19,074
- overdose17,568
- emotional distress15,366
- death14,251
- toxicity to various agents12,632
- drug withdrawal syndrome10,112
- fatigue4,126
- drug ineffective4,075
- drug abuse3,739
- nausea3,739
- anxiety2,931
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 46 |
| 2005 | 60 |
| 2006 | 104 |
| 2007 | 108 |
| 2008 | 181 |
| 2009 | 160 |
| 2010 | 263 |
| 2011 | 272 |
| 2012 | 603 |
| 2013 | 865 |
| 2014 | 771 |
| 2015 | 1,070 |
| 2016 | 2,492 |
| 2017 | 4,304 |
| 2018 | 25,281 |
| 2019 | 3,325 |
| 2020 | 5,469 |
| 2021 | 14,161 |
| 2022 | 15,910 |
| 2023 | 4,654 |
| 2024 | 4,197 |
| 2025 | 4,453 |
| 2026 | 3,265 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Roxicodone (Oxycodone HCl)
2024 spending
$1.6M
Beneficiaries
177
1,525 claims
Per beneficiary
$9,242
$7.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,962,224 |
| 2021 | $2,508,018 |
| 2022 | $1,982,538 |
| 2023 | $1,952,761 |
| 2024 | $1,635,815 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Acute Postoperative Pain Due to Dental Extraction in the Adult Population: A Systematic Review and Network Meta-analysis.
Miroshnychenko A, Ibrahim S, Azab M, et al. · J Dent Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.
Kistemaker KRJ, Sijani F, Brinkman DJ, et al. · Cancer Treat Rev 2024 · Meta-Analysis, Systematic Review
- Hydromorphone for cancer pain.
Li Y, Ma J, Lu G, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Oral tapentadol for cancer pain.
Wiffen PJ, Derry S, Naessens K, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- The role of opioid transmission in music-induced pleasure.
Mas-Herrero E, Ferreri L, Cardona G, et al. · Ann N Y Acad Sci 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Shifting Views on Cancer Pain Management: A Systematic Review and Network Meta-Analysis.
Imkamp MSV, Theunissen M, Viechtbauer W, et al. · J Pain Symptom Manage 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Specgx LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.